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Abstract 26 
Longitudinal data on the E6/E7 mRNA-based AHPV® HPV (AHPV) assay exceeding three years 27 
in comparison to the gold standard digene Hybrid Capture® 2 (HC2) test are not available. 28 
We previously reported the cross-sectional data of the German AHPV Screening Trial (GAST) 29 
where 10,040 women were recruited and tested by liquid-based cytology, the HC2 and the 30 
AHPV assay. 411 test-positive women were followed for up to six years. In addition, 3,295 31 
triple-negative women were screened after a median time of six years. Overall 28 CIN3 cases 32 
were detected. The absolute risk of developing high risk HPV positive CIN3+ over six years 33 
among those women that tested negative at baseline was 2.2 (1.0-4.9) and 3.1 (1.7-5.7) per 34 
1,000 women screened by the HC2 and the AHPV test, the additional risk in AHPV negative 35 
compared with HC2 negative was 0.9 (-0.2 to 2.1) per 1,000, whereas the absolute risk 36 
following a negative LBC test was 9.3 (2.9-30.2). The relative sensitivity of AHPV compared to 37 
HC2 was 91.5% for CIN3+ and the negative predictive values were 99.8 (99.5-99.9) for HC2 38 
and 99.7 (99.4-99.8) for AHPV.  39 
Our data show that the longitudinal performance of the AHPV-test over six years is 40 
comparable to the performance of the HC2 test and that the absolute risk of CIN3+ over six 41 
years following a negative AHPV result in a screening population is low. 42 
 43 
Keywords 44 
AHPV HPV, cervical cancer screening, E6/E7 mRNA, cervical intraepithelial neoplasia   45 
 46 
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Introduction 48 
Systematic screening has led to a significant decrease in cervical cancer cases worldwide. 49 
Since persistent human papillomavirus (HPV) infection with 13 high risk HPV (HR HPV) types 50 
defined as class I or IIA carcinogenic for women (1) is a necessary prerequisite for 51 
development of precancerous lesions and cervical neoplasia, tests for HR HPV infections 52 
have been developed and validated. Incorporation of molecular HPV testing into cervical 53 
cancer screening programmes results in fewer cases of cancer and high-grade cervical 54 
intraepithelial neoplasia (CIN3) being detected at the second screening round in those who 55 
were tested by HPV-tests compared to women screened by cytology only (2-8). The lower 56 
risk following HPV testing suggests that extended screening intervals are appropriate (9-11), 57 
which also avoids detection of transient infections in consecutive screening rounds leading 58 
to overtreatment.  59 
Currently more than 190 HPV assays are commercially available (12) and many countries 60 
have implemented HPV tests in their cervical cancer screening programmes, while other 61 
countries are in the process of switching from cytological screening to primary HPV testing 62 
or co-testing (9, 13, 14), and national cervical cancer screening guidelines have been adapted 63 
accordingly (13). Five group tests are approved by the FDA for application in the US and 64 
primarily detect the HR HPV-group. To date only the cobas 4800® HPV Test (Roche, USA) and 65 
the Onclarity HPV Assay (Becton Dickinson) have been approved for first-line primary 66 
screening. The digene Hybrid Capture-2 (HC2) high-risk HPV DNA test (QIAGEN®, Hilden, 67 
Germany) is considered the gold standard of HPV assays as its performance was validated in 68 
a large number of randomized controlled trials and it was the first HPV test receiving FDA 69 
approval to screen patients with ASCUS, or in women 30 years and older the HC2 High-Risk 70 
HPV DNA Test can be used with Pap to adjunctively screen to assess the presence or absence 71 
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of high-risk HPV types. HC2 HPV detection is based on full-length genomic RNA probes for 72 
hybridization with the viral DNA of the 13 high-risk HPV types. Longitudinal data showed a 73 
very low risk of developing cervical cancer over at least five years in women with a negative 74 
HC2 baseline test (15). Four randomized trials have demonstrated that the cumulative 75 
incidence of cervical cancer after a median of 6.5 years after a negative HC2 test was lower 76 
than the cumulative incidence three years after a normal cytology result (10).  77 
However, cross-hybridization of HC2 with at least 26 additional HPV types of low 78 
carcinogenicity or undefined risk, has been detected (16-19), which occasionally can be 79 
found even in a CIN3 (20). Epidemiological data suggest that such lesions are unlikely to 80 
progress to cervical cancer. This makes the use of HC2 as comparator test according to 81 
established consensus guide lines questionable as CIN3 associated with non HR HPV types 82 
(and of low progressive potential) will be detected by the HC2, but not by a test with a more 83 
stringent analytical specificity that detects predominantly class I/IIa carcinogenic types (21).  84 
As stated by Meijer et al., new HPV tests should demonstrate non-inferior sensitivity and 85 
specificity compared with the HC2 test in a representative set of samples from a routine 86 
screening population in a cross-sectional setting (22). However, these guidelines specify that 87 
they apply to DNA-based tests and whether this guideline could also be applied for 88 
validation of RNA-based tests is controversial. A key issue is the definition of a 89 
representative sample (of cases of CIN2+) and which parameters are required to allow for 90 
the extension of screening intervals.  It is argued that RNA positivity is a later event in the 91 
natural history of cervical neoplasia than HPV DNA positivity, hence there is a desire to have 92 
more longitudinal data regarding CIN2+ incidence following a negative RNA-based test to 93 
determine whether it is safe to extend the screening interval after a negative RNA-based 94 
test. 95 
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The AHPV HPV (AHPV) assay (Hologic, SanDiego, USA) is based on target-mediated 96 
amplification for detection of viral mRNA. The test detects the mRNA of the two HPV 97 
oncogenes E6 and E7 of 14 HPV types, which include all high-risk HPV types targeted by the 98 
HC2 assay as well as the class 2B type HPV66 (1, 23). 99 
The RNA-based AHPV test has been compared to the DNA-based HPV tests in a number of 100 
studies, several are typical screening populations (23, 24). In these studies, the AHPV test 101 
consistently demonstrated comparable sensitivities for the detection of CIN2+ or CIN3+, and 102 
superior specificity. 103 
We recently reported the cross-sectional results of the German AHPV Screening Trial (GAST), 104 
where the clinical sensitivities and specificities of the AHPV and the HC2 HPV tests were 105 
determined and compared in cervical samples from 9,451 women aged 30 to 60 years from a 106 
routine screening population (24).  Samples were centrally analysed by liquid based cytology 107 
(LBC), the AHPV assay and the HC2 assay and those women who had a positive result in any 108 
of these tests were referred for colposcopy. There was no statistical difference between the 109 
AHPV and the HC2 test regarding their sensitivities in detecting CIN2 or CIN3+ lesions. The 110 
specificity (<CIN2) and the positive predictive value (CIN2+) of the AHPV test were 111 
significantly improved compared to the HC2 test. The GAST study results are in line with a 112 
previous report by Heideman et al. which confirmed the non-inferiority of the AHPV assay vs 113 
the GP5+/6+ test, and showed that the AHPV test fulfils cross-sectional clinical HPV test 114 
requirements for cervical screening (25). Recently, longitudinal clinical performance of the 115 
AHPV assay compared to the HC2 test was analysed in a prospective clinical study (CLEAR) 116 
including three years of follow-up in 6,201 women (26). Estimated sensitivity of the AHPV 117 
test was similar and specificity slightly higher than those of the HC2 test. After three years of 118 
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follow-up, women, who were HPV-negative (AHPV or HC2) at baseline, had a very low risk of 119 
CIN2+ and CIN3+.  120 
However, longitudinal data from a screening population cohort on the AHPV assay exceeding 121 
three years compared to the gold standard HC2 testing are important for reassurance 122 
especially after the recent introduction of extended screening intervals (≥5 years) in some 123 
national cervical cancer screening programs. To address this lack of data, the GAST trial was 124 
continued by annually inviting all untreated women who remained positive in at least one of 125 
the three tests for follow-up screening. Furthermore, a randomly selected group of 4,000 126 
women who were triple negative at baseline were invited for a second screening round after 127 
a mean of six years. We here report the first longitudinal data of more than three years 128 
regarding cumulative risk for CIN2/3+, clinical sensitivity and NPV for the detection of 129 
histologically reviewed high-grade CIN by the RNA-based AHPV assay in comparison to the 130 
HC2 test. 131 
 132 
  133 
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Materials and Methods 134 
Participants.  135 
Women aged 30 to 60 years from the routine cervical cancer screening population of three 136 
German centres in Tübingen, Saarbruecken, and Freiburg were invited to participate in the 137 
GAST trial. The data of the baseline cross-sectional study have previously been published 138 
(24). Written informed consent was obtained from each participant, and the study protocol 139 
was approved by all relevant ethics committees (Ethik-Kommission Universitätsklinikum 140 
Tübingen, reference no. 475/2008MPG1; Ethik-Kommission Alfred Ludwigs-Universität 141 
Freiburg, reference no. EK Freiburg 63/09; EthikKommission Landesärztekammer Baden-142 
Württemberg, reference no. B-2009-030f; Ethik-Kommission Ärztekammer des Saarlandes, 143 
reference no. 02/10).  144 
 145 
Study design. 146 
The design of the baseline cross-sectional study was described previously (24). In brief, 147 
eligible consenting women (N = 10,040) had single liquid-based cytology samples 148 
(PreservCyt®, Hologic, USA) taken during the annual routine gynaecological examination. 149 
Liquid-based cytology (LBC, ThinPrep® Pap Test, Hologic, USA), the digene Hybrid Capture 2 150 
(HC2) high-risk HPV DNA test, and the AHPV HPV (AHPV) assay were performed on all 151 
samples. All women with a positive result in any of the three screening tests were invited for 152 
colposcopy within 8 weeks of receiving their test results.  153 
For the positive follow-up arm of the GAST trial, all women, who tested positive in any of 154 
these assays and who were not treated because of abnormal colposcopy and/or histology, 155 
were retested annually for up to five years. After a mean interval of six years 4,000 women, 156 
who were triple negative at baseline, were randomly selected and invited to be retested by 157 
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all three tests when attending routine cervical screening (i.e. second screening round). Those 158 
who tested positive in any of the three tests were invited to colposcopy. Rational for the 159 
sample size among women who tested triple negative at baseline can be found in the 160 
supplemental methods. 161 
 162 
Liquid-based cytology. 163 
As previously described for the cross-sectional trial (24), LBC results were evaluated 164 
according to the Munich nomenclature II and translated into the Bethesda System (TBS). LBC 165 
results were considered negative when the result was Pap I/II (equivalent to negative for 166 
intraepithelial lesion or malignancy [NILM]) or Pap IIw (equivalent to inadequate or atypical 167 
cells of undetermined significance [ASCUS]); all other results were considered positive.  168 
 169 
HPV testing.  170 
HPV testing was performed as previously detailed (24). Residual LBC samples were 171 
processed for HPV testing according to the manufacturer’s specifications. Remaining 172 
samples were stored for LiPA Extra genotyping in case of positive HPV test results.  173 
digene Hybrid Capture 2 high-risk HPV DNA testing was performed as described previously 174 
(27), using the Rapid Capture® System (RCS, QIAGEN, Hilden, Germany) according to the 175 
instructions. A cut-off value of relative light units/cut-off (RLU/CO) ratio of 1.0 for positive 176 
test results was used in this study. All PreservCyt® samples with an initial result of >=1 and 177 
<2.5 RLU/CO were retested as recommended by the manufacturer. If the retest result was 178 
>= 1 RLU/CO, the final result was reported as positive. However, if the retest result was 179 
negative, a third test was performed to generate a final two out of three result.  180 
 o
n
 April 24, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
9 
 
The AHPV HPV assay was performed following the manufacturer’s instructions. The earlier 181 
cut-off value of a signal/cut-off (S/CO) ratio of 1.0 instead of the current (0.5) was used 182 
throughout this study to provide continuity of the data. HPV genotyping was carried out 183 
using the INNO-LiPA® HPV Genotyping Extra test (Fujirebio, Gent, Belgium), as described 184 
previously (27, 28).  185 
 186 
Disease Ascertainment and Histopathology. 187 
Women who tested positive in either LBC, the AHPV or the HC2 assay (HPV-positive women) 188 
were referred to colposcopy within 8 weeks. If lesions were detected after application of 189 
acetic acid a biopsy was taken from the suspicious tissue and specimens were processed to 190 
produce H&E stained slides.  Current practice in Germany and some other European 191 
countries is to observe CIN2 lesions instead of treating them immediately, depending on the 192 
individual situation of the patient and her agreement.  After local pathologist review, all 193 
slides were classified using the three-tiered CIN terminology. All slides with abnormal 194 
findings were reviewed by a second pathologist blinded to the first diagnosis and slides with 195 
discordant review results were again reviewed by a third pathologist to reach a consensus 196 
diagnosis (two out of three agreement).   197 
 198 
Statistical analyses.  199 
Prior to analysis, data were plausibility-checked and monitored. This included violation of 200 
inclusion criteria (pregnancy, age below 30 years or above 60 years), and positive Pap test six 201 
months prior to baseline testing as well as HIV infection. Following this the databases were 202 
sealed and sent to the statisticians for statistical analysis. 203 
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Women with at least one positive test at baseline, who had at least one adequate screening 204 
test result on follow-up and who were not treated nor diagnosed with CIN3 or worse at 205 
baseline were eligible for the follow-up analysis. In addition, women who tested negative at 206 
all three tests at baseline and had at least one adequate screening test result during follow-207 
up were eligible for analysis. 208 
We present baseline demographic characteristics from all participants in the study and for 209 
those who attended follow-up. To assess whether there was a statistical difference between 210 
groups we used a chi-squared test to compare those attending follow-up with those who 211 
were eligible to attend but did not.  212 
 213 
Estimating the cumulative risk of CIN3+ (and CIN2+).  214 
The follow-up of women in whom all three baseline screening tests were negative was quite 215 
different from that in women who had one or more positive screening test results at 216 
baseline. Those with all negative results were rescreened once after approximately 6 years. 217 
Women who had a positive result at baseline were invited back at 12-18-month intervals 218 
until the results of all three tests were negative or until they were treated for high-grade 219 
CIN. 220 
At each visit we estimated the hazard of having CIN3+ (or CIN2+) by multiplying the 221 
proportion of tested women who were eligible for colposcopy by the proportion of women 222 
attending colposcopy who were diagnosed with CIN3+ (or CIN2+). Further details can be 223 
found in the supplemental methods. Having estimated the hazard at each visit, we estimated 224 
the cumulative probability of disease after several visits using the Kaplan-Meier (product 225 
limit estimator) approach. The variance of the modified Kaplan-Meier estimator was derived 226 
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in the same way as the Greenwood formula is derived for the usual Kaplan-Meier estimator. 227 
The formula is provided in Supplemental Methods. 228 
We estimated the hazard at baseline separately for each of eight groups based on the result 229 
combinations (positive or negative) for each of the three screening test results. 230 
Subsequently we estimated the hazards separately in just four groups based on the baseline 231 
result combinations of the two HPV tests. There was no evidence that the hazards differed 232 
depending on the LBC result within each of the four groups (and numbers were too small to 233 
estimate hazards separately in each of the eight groups). Since we didn’t have six-year 234 
follow-up data for women who were not triple negative at baseline, we assumed that the 235 
hazard observed at about 6 years in the baseline screen negative group, also applied to all 236 
other groups. 237 
We then estimated the number of cases of CIN3+ (and CIN2+) that would have been 238 
observed among women negative at baseline on each of the three tests (separately) had 239 
everyone been followed to six years by taking a weighted sum of the estimated cumulative 240 
risk in each group. The cumulative risk in each group was also estimated, by dividing the 241 
number of cases by the number of women with that result at baseline.  242 
Confidence intervals were obtained by assuming that the logarithm of the cumulative risk is 243 
approximately normally distributed. P-values are estimated from the discordant pairs using 244 
the exact McNemar significance probability test. 245 
The main analysis presents results including all CIN3 cases. Since we were interested in 246 
comparing the performances of two HPV tests both of which aim to detect the same 13 high-247 
risk HPV types and HPV66 and since CIN3 caused by other HPV types are less likely to 248 
progress to cancer, a sub-analysis excludes disease where the HC2 results are technically 249 
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false positive due to cross-hybridization with non-carcinogenic HPV types (i.e., we include 250 
only lesions positive for one of the 13 types classified as class I/IIa carcinogenic to humans).  251 
Analyses were carried out using STATA 15 (StataCorp, 15.0). 252 
  253 
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Results 254 
Out of the 4,000 women with negative screening test results at baseline invited, 3,295 255 
(82.4%) attended follow-up. Among those with at least one positive test at baseline 606 256 
were eligible for follow-up and 411 (67.8%) attended (Figure 1). Baseline demographic 257 
characteristics of women eligible for analysis at baseline and follow-up are presented in 258 
Table 1.  Women who participated in the cross-sectional study were broadly similar to those 259 
who attended follow-up. There were only slight differences in education and number of 260 
sexual partners between women attending follow-up and those eligible, but who did not 261 
attend. 262 
 263 
Results for women on follow-up after a positive baseline test result. 264 
Untreated women with at least one positive test result at baseline and no CIN3 or worse 265 
were invited to attend annual follow-up examinations over a 5 year-period (N=606). Follow-266 
up ceased when HPV infection and/or cervical abnormalities were cleared, if treated for 267 
cervical disease, or if they refused to participate in the follow-up study. Of the eligible 268 
women 411 (67.8%) attended at least one follow-up examination and were eligible for 269 
analysis. The median time to the first follow-up visit was 14 months (range 6 to 80 months) 270 
(Figure S1) and the average number of follow-up visits per participant was 1.7 (range 1-5). 271 
Three women were excluded, because they were missing a HC2 test and did not return for 272 
follow-up. Of the 408 women with at least one follow-up visit with adequate HC2 and AHPV 273 
results, 77.2% (315) were negative on both HPV tests at their final visit. In total 200 women 274 
tested positive during follow-up and were referred to colposcopy; 165 (82.5%) of these 275 
women attended colposcopy. Ninety percent of those who attended follow-up did within 2.5 276 
years of baseline. A total of 32 women were diagnosed with CIN2 or worse during follow-up. 277 
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Follow-up HPV test results by visit number among those with a positive screening test at 278 
baseline are detailed in supplementary Table S1. No LBC test results were missing, but 10 279 
women had both HPV tests missing and 19 were missing the HC2 test on at least one 280 
appointment. The agreement of the HPV tests (when both were available) was substantial 281 
with a kappa value of κ = 74.7% (95% CI 69.7% to 79.7%). 282 
During follow-up of those women who tested positive on at least one test at baseline, a total 283 
of 24 women were diagnosed with CIN3 and 8 with CIN2 (Table 2). Baseline test result and 284 
numbers diagnosed with CIN2+ during follow-up are shown in Table 2. 24 CIN2+ lesions 285 
(75%) were detected in women with negative cytology and with at least one positive HPV 286 
test result and 8 (25%) in women who tested triple positive at baseline. At baseline, HC2 was 287 
negative in one CIN2 and two CIN3 cases, whilst AHPV was negative in one CIN2 and five 288 
CIN3 cases that developed during follow up (data not shown). One of the 5 CIN3 with 289 
discordant HR HC2 positive and AHPV negative HPV test results at baseline was identified by 290 
genotyping as HPV 82, which is not targeted by either assay and which is not a HR type. No 291 
adenocarcinoma in-situ (AIS) or invasive cervical cancer cases were detected during follow-292 
up. 293 
 294 
Longitudinal results for women who tested negative at baseline. 295 
In the baseline cross-sectional arm of the German AHPV Screening Trial (GAST), 8,752 296 
women had a negative result in all three tests (cytological screening, Hybrid Capture 2 (HC2) 297 
and AHPV). Of these, 4,000 participants were invited for follow-up testing approximately six 298 
years post enrolment. In total 3,295 (82.4%) attended follow-up (Figure 1). The median time 299 
between baseline and attendance at the second round was 6.2 years (range 3.9-8.5).  300 
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At the second round 3,057 women tested negative on all three tests (92.8%). A total of 140 301 
women (4.6%) had at least one positive test results at follow-up, 115 (82%) of these 302 
underwent a colposcopic examination and a total of 9 women were diagnosed with CIN2 or 303 
worse disease (5 CIN2 and 4 CIN3 lesions).  A summary of LBC and HPV tests results at the 304 
second screening round is found in Table 3. The level of agreement between the HPV tests 305 
was substantial with a kappa value of κ = 81.1 (95%CI: 78.0-93.8). 306 
Sensitivity of cytology for the detection of CIN3+ was 44% (N=4 of 9), but 100% tested HPV 307 
positive (Table 4). One CIN3 case, which tested HC2 positive and AHPV negative, revealed in 308 
the histopathology a small lesion of 0.2 mm that was regressive and showed signs of 309 
inflammation. HPV 16 was detected in all patients with CIN3 by LiPA- Extra genotyping test.  310 
In the present study we observed 10 of 23 untreated (43%) CIN2 cases that regressed, while 311 
3/23 (13%) progressed to CIN3. 312 
Passive clinical follow-up data were available from a registry on the complete Saarbrücken 313 
sub-cohort of 2,147 women who tested triple-negative at baseline, 887 of those women 314 
attended follow-up as part of GAST. During a six years passive follow-up period only one 315 
CIN1 and one CIN2 case were observed in women who did not attend the second-round 316 
screening in GAST. Among the Saarbrücken cohort attending the second screening round, 317 
one case of CIN2 and two cases of CIN3 were detected at the second screening appointment. 318 
 319 
HPV-types in samples with high grade disease. 320 
All HPV-positive samples were genotyped by the LiPA-Extra genotyping test. Baseline HPV 321 
test results among the 41 women who went on to be diagnosed with CIN2+ during follow-up 322 
show that 9 (22%) were HPV negative, 2 (5%) tested positive to non-HC2 risk HPV types (66 323 
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and 82), 24 (58%) single and 8 (20%) multiple HPV infections were detected (results not 324 
shown).   325 
HPV genotyping results at the time of diagnosis (during follow-up) are presented in Table S2. 326 
At the time of diagnosis 1/41 (2%) CIN2 was HPV negative on both tests, one CIN2 and one 327 
CIN3 (5%) tested positive to non-high risk HPV types (53, 66 and 82), 28/41 (68%) single and 328 
12/41 (29%) multiple HPV infections were detected.  329 
HPV16 was the most frequent HPV-type detected in patients with CIN3 in the cross-sectional 330 
part of the study and among those attending follow-up. 331 
 332 
Cumulative risk of disease during the study period. 333 
The main analysis presents results including all diagnosed disease. We present a sub-analysis 334 
excluding two CIN3 cases whose HPV types were 82 and 67 and hence were considered 335 
technically false positive HC2 test results. One case (HPV 67) was diagnosed and treated at 336 
baseline, the remaining case (HPV 82) was diagnosed at follow-up.   337 
 338 
A summary of the 6-year cumulative risk per 1,000 women screened and negative predictive 339 
value among women testing negative at baseline can be found in Table 5. Risk per 1,000 340 
women screened by time since baseline test is presented in Figure 2 and 3. Note that the 341 
vast majority of women negative on any one screening test were negative on all three and 342 
were therefore not rescreened until 6 years. This explains the sudden jump in the risk at 6-343 
year visits. 344 
 345 
CIN2 or worse. 346 
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Cumulative risk of CIN2 or worse by the 6-year visit was 0.62% (95%CI: 0.24% to 1.59%) and 347 
0.47% (95%CI: 0.27% to 0.81%) among those who tested AHPV and HC2 negative, 348 
respectively. The difference in AHPV negative was 0.15% (95%CI: 0.38% less to 0.69% more) 349 
and is not significant (p= 0.096). For comparison the cumulative risk by 6 years among LBC 350 
negative women was 1.66% (0.72% to 3.83%). The relative sensitivity for CIN2+ of AHPV in 351 
comparison to HC2 was 91.4%. Among women testing negative on both HPV tests at 352 
baseline, the cumulative risk of CIN2 or worse was 0.38% (95%CI: 0.17% to 0.86%). 353 
 354 
The sub-analysis excluding one case (diagnosed at follow-up) of CIN3 which tested HPV 82 355 
positive and one (diagnosed at baseline) that tested HPV 67 positive, produced very similar 356 
results : 0.59% (0.22% to 1.61%) and 0.47% (0.27% to 0.81%) among AHPV and HC2 negative 357 
women, respectively. The relative sensitivity for CIN2+ of AHPV in comparison to HC2 was 358 
93.0%.  359 
 360 
CIN3. 361 
Cumulative risk of CIN3 disease by the year-6 visit was 0.31% (95%CI: 0.17% to 0.57%) and 362 
0.22% (95%CI: 0.10% to 0.49%) for AHPV negative and HC2 negative women (Table 5), 363 
respectively: difference 0.09% (95%CI -0.02% to 0.21%). The cumulative risk by the year-6 364 
visit among those testing LBC negative was 0.93% (0.29% to 3.02%). The relative sensitivity 365 
for CIN3 of the AHPV test in comparison to HC2 was 91.5%. Among women testing negative 366 
on both HPV tests at baseline, the cumulative risk of CIN3 was 0.17% (95%CI: 0.04% to 367 
0.75%). 368 
 369 
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The sub-analysis excluding two CIN3 cases with technically false positive HR HC2 HPV type 370 
results, produced cumulative risks by 6 years of 0.28% (0.14% to 0.54%) among those who 371 
tested AHPV negative at baseline and 0.22% (0.10% to 0.49%) among those who tested HC2 372 
negative (p= 0.1094). The cumulative risk by 6 years among those testing LBC negative was 373 
0.90% (0.27% to 3.04%). The relative sensitivity of AHPV to HC2 for CIN3 increased to 94.2%.  374 
There were only 20 women with a signal/cut-off ratio of between 0.5 and 1.0 on the AHPV 375 
test at baseline, they were all HC2 negative and LBC negative. Only four of these 20 women 376 
attended follow-up where they were found to still be HPV negative. 377 
  378 
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Discussion  379 
In recent years, many countries integrated HPV testing into their national cervical cancer 380 
screening programmes. Compared to conventional methods, HPV testing increases early 381 
detection rates of precancerous and cancerous lesions and allows extended screening 382 
intervals. However, the optimal lengths of screening intervals for women with negative 383 
results remains to be established and might greatly depend on the long-term predictive 384 
values of a given HPV test. Longitudinal clinical performance data have so far been published 385 
for only a small number of HPV tests. Ronco et al. presented pooled data from four studies 386 
on the performance of the DNA-based HC2 assay over a median of 6.5 years follow-up 387 
period (10). In addition, there is evidence regarding the good negative predictive value over 388 
three years for the cobas 4800® test (Roche Diagnostics) (29), over three years for the 389 
Abbott RealTime HPV DNA-test (30) and over three years for the RNA-based AHPV test (26). 390 
During the revision of our manuscript, data comparing the AHPV with the cobas 4800 HPV 391 
test using biobanked material were published that demonstrate a non-inferior longitudinal 392 
sensitivity and NPV over 7 years for the AHPV (31). 393 
In the present study we evaluated the extended predictive value of the RNA-based AHPV 394 
HPV test in comparison to the DNA-based HC2 test over a 5-6-year period by focussing on 395 
the cumulative risks for CIN3+ six years after a negative baseline result. In our opinion CIN2+ 396 
is a less reliable endpoint because it is an equivocal histological diagnosis and regression 397 
rates are high, as observed in our study with a percentage of 43%. An advantage of this 398 
study therefore was that many CIN2 lesions were not treated immediately and were seen to 399 
regress during surveillance. 400 
During the course of the follow-up of women who tested positive (LBC, AHPV or HC2) at 401 
baseline, we detected 8 CIN2 and 24 CIN3 cases. One CIN2 case was missed by both HPV 402 
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tests and was positive only by cytology. One CIN3 case tested negative by AHPV at the time 403 
of diagnosis, but was detected by HC2 and it contained a non-HR type (HPV82). Results from 404 
a meta-analysis of type specific HPV DNA prevalence in cervical cancer and women with 405 
normal cytology showed a prevalence of HPV82 of 0.1% (95% CI 0.1-0.3) and 0.1% (95% CI 406 
0.0-0.1), respectively. HPV82 is not targeted by the HC2 test, but may yield positive results 407 
due to cross-reaction. The known extensive cross-reactivity of the HC2 test may therefore 408 
explain the non-significantly higher sensitivity compared to the AHPV test in the baseline 409 
and follow up results of this study. According to the Meijer criteria (22) the candidate test 410 
should have a clinical sensitivity for CIN2+ not lower than 90% of the clinical sensitivity of the 411 
HC2 in women aged at least 30 years. Clearly the results for AHPV at 6 years achieved clinical 412 
sensitivity rates exceeding this 90% threshold, regardless if all CIN2+ cases were included or 413 
if CIN2+ with non-carcinogenic types were excluded.  414 
In the second screening round of women who tested triple negative at baseline a total of five 415 
CIN2 and four CIN3 cases were identified of which one CIN3 was missed by the AHPV test at 416 
follow-up. This case was HPV16-positive and was detected repeatedly positive by the HC2 417 
test at relative light units (RLUs) of 1.86, 1.53 and 1.51, which is a borderline positive result 418 
according to the FDA approval, but a negative test result in some countries (e.g. United 419 
Kingdom), where an increased cut-off of 2.0 RLUs is used for cervical cancer screening.  420 
 421 
The cumulative risks of CIN3+ 6 years after a negative screening test in this study are very 422 
similar to the ones observed earlier by Dillner et al. (15). In both studies, the cumulative 423 
incidence in women with baseline negative cytology was around 1%. The cumulative 424 
incidence after a negative AHPV in this study was substantially lower: 0.31% (0.17% to 425 
0.57%). This is in line with one previous publication where very low three-year risks for 426 
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CIN3+ were detected after a negative baseline AHPV test (26). In our study, the upper 95% 427 
confidence limit for the additional risk after a negative AHPV compared with a negative HC2 428 
was 0.21%. If it is accepted that women do not need to be re-screened until their risk of 429 
CIN3+ reaches 0.5%, this study has shown that it is safe to use an interval of 5-6 years after a 430 
negative AHPV test. 431 
The analyses including all CIN3 cases detected or excluding two CIN3 (one from baseline with 432 
HPV67 and one detected at follow up with HPV82) revealed highly comparable absolute risks 433 
for CIN3+ following a negative baseline HC2 or AHPV test and comparable longitudinal 434 
negative predictive values (NPV) of both tests. Note that women who tested positive (on any 435 
test) at baseline were not asked to return for testing 6 years after enrolment. Therefore we 436 
assumed that the hazard at 6 years among those who tested positive but who did not 437 
develop disease was the same as that observed at about 6 years in the baseline screen 438 
negative group. This explains the sudden jump in the risk in figure 2 and 3 after 5 years. 439 
Altogether, we found an absolute risk for developing CIN3+ after six years among those 440 
women who tested negative at baseline of 2.2 and 3.1 per 1,000 women screened by the 441 
HC2 and the AHPV test, respectively. This difference is not significant and is in line with one 442 
previous publication where very low three-year risks for CIN3+ were detected after a 443 
negative baseline AHPV test (26). 444 
The fact that annual follow-up of all women from the routine screening population was 445 
unachievable complicated the data analysis and might be considered a weakness of this 446 
study. However, the CLEAR study found that annual follow up of screen-negative women 447 
suffers from low compliance (26) and is not recommended by national and European guide 448 
lines. Passive follow-up of those women who tested triple-negative at baseline was possible 449 
in a subset of 2,147/8,752 (25%) women and showed that we were unlikely to have missed 450 
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disease by only rescreening at 6 years. On the other hand, this study strongly benefits from 451 
the large number of participating women, the prospective study design and the extended 452 
follow-up period of six years. Another strength of this study is that all positive samples (LBC, 453 
AHPV or HC2) were genotyped, which enabled a detailed analysis of discordant test results.  454 
The poor sensitivity of LBC in this study may be considered a weakness, but simply reflects 455 
the low single-round sensitivity of cytology in Germany that has been noted in several 456 
studies previously (32). Since the primary comparison is between AHPV and HC2 the poor 457 
sensitivity of LBC does not affect the overall results.  458 
 459 
In summary, numerous studies from different populations (23) consistently demonstrated a 460 
similar cross-sectional sensitivity paired with higher clinical specificity when AHPV was 461 
compared to other FDA approved HPV DNA tests, which reduces the costs of follow-up. With 462 
regard to the extended intervals in some cervical cancer screening programs data for 463 
screening intervals up to 3 years have already been published, as well as a retrospective 464 
analysis over 7 years (31). With the present study we add prospective data of the 465 
longitudinal performance over a 5-6 year period showing that the cumulative risk for CIN2/3 466 
and the NPV of the AHPV is non-significantly different from the HC2 assay. We conclusively 467 
demonstrate low absolute risks for CIN3+ following a negative AHPV test suggesting that the 468 
extended screening intervals proposed for use with HC2 are safe with AHPV too. 469 
  470 
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Figure legends 592 
Figure 1: Follow-up Flow chart. Green indicates the cohort which tested triple-negative (LBC, 593 
HC2 and AHPV) at baseline. Red indicates the cohort who tested positive in at least one test 594 
(LBC, HC2 or AHPV) at baseline.  595 
 596 
Figure 2: Cumulative risk per 10,000 women becoming CIN2+ following a negative baseline 597 
result in the respective test. Data have been analysed by visit. Visits should have been 598 
annual up to 5 years in those with a positive test and at 6 years for triple negatives at 599 
baseline. LBC, liquid based cytology. 600 
 601 
Figure 3: Cumulative risk per 10,000 women becoming CIN3+ following a negative baseline 602 
result in the respective test. Data have been analysed by visit. Visits should have been 603 
annual up to 5 years in those with a positive test and at 6 years for triple negatives at 604 
baseline. LBC, liquid based cytology. 605 
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Tables 607 
Table 1. Baseline demographic characteristics of women in the GAST Trial 
Characteristic reported 
at baseline 
Attended 
follow-up 
Eligible for 
analysis at 
baseline Chi2 test* 
Age at enrolment N % N % 
 30-34 611 16.5 1623 17.2 
 35-39 692 18.7 1696 17.9 
 40-44 852 23.0 2123 22.5 
 45-49 734 19.8 1873 19.8 
 50-54 499 13.5 1295 13.7 
 55-59 318 8.6 841 8.9 
 Missing 0 - 0 - 
 Total (Not missing) 3706   9451   x25=5.163, p=0.396 
Education 
     Missing 384 - 1663 - 
 None 13 0.4 34 0.4 
 Primary 602 18.1 1383 17.8 
 College 1503 45.2 3350 43.0 
 University 1204 36.2 3021 38.8 
 Total (Not missing) 3322   7788   x23=17.16, p=0.001 
Number of sexual partners 
    Missing 1016 - 3107 - 
 One 921 34.2 2195 34.6 
 Two to four 1019 37.9 2282 36.0 
 Four or more 750 27.9 1867 29.4 
 Total (Not missing) 2690   6344   x22=8.6423, p=0.013 
Age at first sexual intercourse 
    Missing 737 - 2448 - 
 Under age 18 1660 55.9 3855 55.0 
 Age 18 or older 1310 44.1 3148 45.0 
 Total (Not missing) 2970   7003   x21=1.4558, p=0.228 
*Note the X2 test compares those attending to those not attending among 
those eligible for follow-up  
 608 
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Table 2. Baseline HPV test results among women with CIN2+ during 
follow-up 
LBC HC2 AHPV CIN2 CIN3 
+ + + 2 6 
- + + 4 11 
- + - 1 5* 
- - + 1 2 
*One case was positive for HPV82 on LIPA and is 
excluded in the sub- analysis 
 610 
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Table 3. Second round LBC and HPV test results among women who were triple negative at 
baseline 
HPV test result 
during follow-
up (HC2/AHPV) LBC negative 
LBC 
inadequate 
LBC low-
grade (Pap 
III) 
LBC high-
grade (Pap 
IIID) Total 
Number 
with 
CIN2+ 
Both missing 71 4 0 0 75 0 
Missing HC2 1 0 0 0 1 0 
Missing AHPV 4 0 0 0 4 0 
-/- 3057 18 5 12 3092 0 
-/+ 13 0 0 0 13 0 
+/- 48 0 1 1 50 1 
+/+ 44 0 3 13 60 8 
Total 3238 22 9 26 3295 9 
 612 
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Table 4. Second round screening HPV test results among women with 
CIN2+ during follow-up 
LBC HC2 AHPV CIN2 CIN3+ 
+ + + 3 1 
- + + 2 2 
- + - 0 1 
- - + 0 0 
Note the one CIN3+ with discordant HPV test 
results was also negative on LBC as were two 
other CIN3 and two CIN2. 
 614 
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 616 
Table 5. 6-year cumulative incidence, risk per 1000 women screened and negative predictive value among those 
testing negative at baseline. 
  Cumulative incidence, 95% CI 
Risk per 1,000 women 
screened, 95% CI 
Negative predictive value*, 95% 
CI 
CIN2 or worse                       
AHPV Negative 0.62% 0.24% to 1.59% 6.2 2.4 to 15.9 99.38% 98.41% to 99.76% 
HC2 Negative 0.47% 0.27% to 0.81% 4.7 2.7 to 8.1 99.53% 99.19% to 99.73% 
LBC Negative 1.66% 0.72% to 3.83% 16.6 7.2 to 38.3 98.34% 96.17% to 99.28% 
CIN3 or worse                       
AHPV Negative 0.31% 0.17% to 0.57% 3.1 1.7 to 5.7 99.69% 99.43% to 99.83% 
HC2 Negative 0.22% 0.10% to 0.49% 2.2 1.0 to 4.9 99.78% 99.51% to 99.90% 
LBC Negative 0.93% 0.29% to 3.02% 9.3 2.9 to 30.2 99.07% 96.98% to 99.71% 
*Note the NPV is estimated excluding the risk among those attending the second round of screening 
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